NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc. (NGM) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · NGM · as of Jun 9, 2026
Activity summary
Buy transactions
10
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
∞
Buy/Sell (by trades)
Overall sentiment
NGM Biopharmaceuticals, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
NGM insider buying and selling by quarter
NGM insider selling · NGM insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Recent insider transactions
NGM executive sell shares · NGM board member insider trading · NGM insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Apr 5, 2024 | TCG Opportunity III GP, LLC 10 percent owner | Other | 1,000 | — | Form 4 |
| Apr 5, 2024 | TCG Opportunity III GP, LLC 10 percent owner | Other | 44,000 | — | Form 4 |
| Apr 5, 2024 | COLUMN GROUP GP, LP 10 percent owner | Other | 1,000 | — | Form 4 |
| Apr 5, 2024 | COLUMN GROUP GP, LP 10 percent owner | Other | 44,000 | — | Form 4 |
| Apr 5, 2024 | COLUMN GROUP L P Director | Other | 1,000 | — | Form 4 |
| Apr 5, 2024 | COLUMN GROUP L P Director | Other | 44,000 | — | Form 4 |
| Apr 5, 2024 | GOEDDEL DAVID V Director | Other | 1,000 | — | Form 4 |
| Apr 5, 2024 | GOEDDEL DAVID V Director | Other | 100,000 | — | Form 4 |
| Apr 5, 2024 | Pierce Valerie L See Remarks | Other | 26,458 | $41K | Form 4 |
| Apr 5, 2024 | RIEFLIN WILLIAM JL Director | Other | 2,769,168 | — | Form 4 |
| Apr 5, 2024 | Viret Jean-Frederic CFO | Other | 3,038 | $5K | Form 4 |
| Apr 5, 2024 | WOODHOUSE DAVID J CEO · Director | Other | 23,993 | $37K | Form 4 |
| Apr 5, 2024 | WOODHOUSE DAVID J CEO · Director | Other | 97,654 | — | Form 4 |
| Apr 5, 2024 | Perlich Irene PAO | Other | 6,284 | $10K | Form 4 |
| Apr 5, 2024 | Hooper Suzanne Sawochka Director | Other | 7,000 | $11K | Form 4 |
| Apr 5, 2024 | Lieu Hsiao D Chief Medical Officer | Other | 19,349 | $30K | Form 4 |
| Jan 16, 2024 | Lieu Hsiao D EVP, CHIEF MEDICAL OFFICER | Other | 5,430 | $7K | Form 4 |
| Jan 16, 2024 | Perlich Irene PRINCIPAL ACCOUNTING OFFICER | Other | 1,025 | $1K | Form 4 |
| Jan 16, 2024 | Pierce Valerie L SVP, GC & CCO | Other | 5,021 | $7K | Form 4 |
| Jan 16, 2024 | WOODHOUSE DAVID J CHIEF EXECUTIVE OFFICER · Director | Other | 13,032 | $17K | Form 4 |
| Nov 16, 2023 | COLUMN GROUP L P Director | Purchase | 5,840 | $4K | Form 4 |
| Nov 15, 2023 | COLUMN GROUP L P Director | Purchase | 16,791 | $12K | Form 4 |
| Nov 16, 2023 | GOEDDEL DAVID V Director | Purchase | 5,840 | $4K | Form 4 |
| Nov 15, 2023 | GOEDDEL DAVID V Director | Purchase | 16,791 | $12K | Form 4 |
| Nov 16, 2023 | GOEDDEL DAVID V Director | Purchase | 1,460 | $907 | Form 4 |
TCG Opportunity III GP, LLC
10 percent owner
Date
Apr 5
Shares
1,000
Price
—
Value
—
TCG Opportunity III GP, LLC
10 percent owner
Date
Apr 5
Shares
44,000
Price
—
Value
—
Lieu Hsiao D
Chief Medical Officer
Date
Apr 5
Shares
19,349
Price
$1.55
Value
$30K
Lieu Hsiao D
EVP, CHIEF MEDICAL OFFICER
Date
Jan 16
Shares
5,430
Price
$1.34
Value
$7K
Perlich Irene
PRINCIPAL ACCOUNTING OFFICER
Date
Jan 16
Shares
1,025
Price
$1.34
Value
$1K
WOODHOUSE DAVID J
CHIEF EXECUTIVE OFFICER · Director
Date
Jan 16
Shares
13,032
Price
$1.34
Value
$17K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About NGM insider trading
NGM insider trades
NGM Biopharmaceuticals, Inc. (NGM) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including NGM. Over the past 12 months, 0 insiders have filed transactions with the SEC. NGM insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For NGM Biopharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
NGM insider trading · 5 questionsThe insiders of NGM Biopharmaceuticals, Inc. (NGM) include executives and directors such as NGM, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026